Licarbium

Quick links to important sections

Licarbium

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Licarbium

Quick Facts

Property Description
Active ingredient Lithium Carbonate / Lithium Citrate
Form Tablet, Capsule, Oral Solution (including Extended-Release options)
Pharmacological class Mood Stabilizer, Antimanic Agent
General purpose Stabilizing mood and preventing extreme affective episodes
Origin Derived (Synthetic salt from the element Lithium)

What Type of Medication is Licarbium?

Licarbium is a foundational prescription psychotropic drug primarily classified as a Mood Stabilizer and an Antimanic Agent. Its defining active component is a Lithium salt, typically formulated as Lithium Carbonate or sometimes Lithium Citrate. This classification is clinically recognized for addressing severe episodic mood fluctuations, with Lithium being a unique small molecule treatment. The medication helps to stabilize emotional states, providing long-term stability by preventing the recurrence of severe mood fluctuations. It is recognized as a standard component of psychiatric care.

Licarbium Composition and Drug Forms

Licarbium is a single-agent product whose therapeutic effect is derived entirely from the salt of the element Lithium, a synthetic salt prepared for the oral route of administration. The medication is available in several distinct dosage forms, including standard tablets and capsules, alongside specialized extended-release or slow-release formulations. The use of these controlled-release forms is a defining characteristic of Lithium treatment, allowing for stable maintenance of the necessary narrow therapeutic concentration in the body. The active ingredient, Lithium, shares its profile with other commercially available preparations, such as Lithobid and Camcolit, serving as the common therapeutic foundation.

How Does Licarbium Generally Benefit Mood Stability?

The general purpose of Licarbium is to help patients maintain affective equilibrium by regulating crucial processes within the Central Nervous System (CNS). It achieves this by complex physiological actions that involve adjusting the flow of electrically charged particles (cations) and influencing intracellular messaging pathways inside nerve cells. This unique mode of action results in the stabilization of nerve signals, helping to prevent the onset of both the overly elevated and the severely depressive periods characteristic of mood disorders. Clinical application for long-term benefits confirms that Lithium treatment is utilized for relapse prevention in patients with bipolar disorder.

Regulatory References

  1. NIH MeSH Descriptor for Lithium Carbonate
  2. WHO Essential Medicines List entry for Lithium Carbonate

What side effects are possible with Licarbium?

Possible side effects and safety information

The safety profile for Licarbium, which contains a lithium salt, is characterized by a narrow therapeutic index, meaning the effective serum concentration is close to the level that may cause toxicity, necessitating mandatory monitoring of serum levels as defined in official regulatory documents (DailyMed, EMA SmPC).

Adverse reactions are formally classified based on frequency and are grouped according to the major physiological systems they affect.

Frequency Classification Documented Adverse Reactions (Examples)
Common / Very Common Fine hand tremor, polyuria (increased urination), polydipsia (increased thirst), mild nausea, vomiting, and weight gain [FDA Label].
Long-Term Exposure Risk Potential for changes in renal function (including nephrogenic diabetes insipidus) and thyroid function (hypothyroidism or goiter) [FDA Label].

Serious adverse reactions documented in regulatory sources include acute Lithium toxicity (symptoms like severe confusion, ataxia, and coarse tremor), the potential for long-term chronic kidney disease, and cardiac effects like arrhythmias. Effects such as tremor and mild gastrointestinal upset may be more prominent at the beginning of treatment or during dose escalation, according to official labeling.

Population-Specific Safety Considerations

Official prescribing information addresses safety for specific populations. The use of the medication in older adults requires particular caution due to an increased risk of toxicity. Regarding pregnancy, official documents note a potential increase in the risk of cardiac anomalies (Ebstein's anomaly) if exposure occurs during the first trimester. The medication is also known to be excreted into breast milk.

Overdose and Emergency Response

Overdose Manifestations and When to Seek Help

Overdose with Licarbium (Lithium) results in lithium toxicity, which is directly related to high serum lithium concentrations. The condition presents with a spectrum of officially documented symptoms, ranging from early signs of toxicity to severe, life-threatening outcomes.

Documented Signs of Lithium Toxicity

Severity Manifestations (Official Labeling)
Early/Mild Persistent diarrhea, vomiting, fine hand tremor, ataxia (lack of coordination), and muscular weakness.
Severe Confusion, stupor, seizures, coma, hyperreflexia, and blurred vision.

Required Emergency Actions

The regulatory documentation mandates specific actions when signs of toxicity appear. If Early/Mild symptoms occur, the medication must be discontinued immediately, and a healthcare provider must be contacted without delay.

Immediate Emergency Assistance is Required if severe manifestations are present. This includes cardiovascular effects such as fainting, abnormal heart beats, or hypotension, as well as the onset of seizures or profound confusion. Severe toxicity may lead to irreversible neurological complications or acute renal failure. Official prescribing information states that no specific antidote for lithium poisoning is known, and treatment is supportive, often requiring intensive monitoring and procedures such as hemodialysis.

Therapeutic Uses of Licarbium

What Licarbium Treats: Main Uses and Benefits

Licarbium, a commonly used mood stabilizer, is primarily used in clinical settings to manage severe, episodic shifts in affect and behavior. Its therapeutic value lies in providing comprehensive support across conditions characterized by periods of heightened symptoms and intense, fluctuating symptom patterns. In practice, lithium is applied to address conditions associated with acute or disruptive episodes.

Quick Fact: Relief for Extreme Affective States

Use Context Symptoms Managed Primary Benefit
Acute Care Mania, Impulsivity, Severe Irritability May assist with functional stability
Long-Term Recurrent Episodes (Manic/Depressive) Supports affective equilibrium/prophylaxis
Refractory Persistent Low Mood (Augmentation) Contributes to more complete symptomatic relief

Therapeutic Domains

The core uses of Licarbium involve the stabilization of extreme mood swings in Bipolar Disorder, its role in maintenance therapy to help manage the risk of recurrence, and its use as an augmenting agent for recurrent or difficult-to-treat depression. It is relevant for managing symptom clusters like racing thoughts, severe irritability, and hyperactivity, as well as providing a distinct benefit in assisting with managing the risk of suicidal thoughts and actions. This use may assist with maintaining functional stability and supports general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Licarbium (Lithium) eligibility is strictly defined by regulatory documents, focusing on a patient's organ function, age, and physiological state. The medication is contraindicated and must not be used in specific populations. These mandatory exclusions include patients with severe renal impairment, a known history of Brugada syndrome or other significant cardiovascular disease, and those experiencing severe dehydration or sodium depletion. Use is also generally contraindicated during breastfeeding.

Regulatory guidelines establish specific age thresholds. Licarbium is approved for use in adults and has established use in pediatric patients aged seven years and older for standard formulations. For controlled-release forms, use is generally established from the age of twelve. Efficacy and safety are not established for children under seven years.

For other groups, use is classified as conditional or restricted. Older adults require cautious use due to the potential for toxicity at lower serum levels. Patients with mild to moderate renal impairment must be closely monitored, and use is restricted if they are simultaneously taking certain interacting medications, such as diuretics.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Licarbium (Lithium) interactions are primarily documented in regulatory sources as highly dependent on its renal clearance and the subsequent risk of plasma concentration increase. The official prescribing information defines interactions through two main domains: pharmacokinetic changes and pharmacodynamic additive effects.

Pharmacokinetic Interactions (Altered Clearance)

Many common drug categories may significantly increase Licarbium serum concentrations by reducing its elimination through the kidneys, which is a pharmacokinetic interaction. These include Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Thiazide Diuretics, and agents affecting the renin-angiotensin system, such as ACE Inhibitors and Angiotensin II Receptor Antagonists (ARBs). Conversely, agents like Acetazolamide and Urea may officially decrease Licarbium levels by increasing its urinary excretion.

Pharmacodynamic Interactions (Additive Effects)

Co-administration with certain medicinal products carries official warnings regarding potential synergistic effects. Combining Licarbium with Serotonergic Agents (like SSRIs or Triptans) is documented as increasing the risk of Serotonin Syndrome. The co-administration with Antipsychotics or certain Calcium Channel Blocking Agents is associated with an increased risk of neurotoxicity and adverse neurological reactions.

Official Restrictions and Considerations

The regulatory label advises against co-administration in patients experiencing conditions that severely reduce clearance, such as severe sodium depletion or dehydration, due to the high risk of accumulation. The interaction profile is also officially noted as being heightened in patients with Impaired Renal Function.

Mechanism of Action

Inhibiting Key Intracellular Enzymes and Signaling Pathways

Licarbium's action centers on the Lithium ion ( Li^+) directly inhibiting enzymes such as Inositol Monophosphatase (IMPase) and Glycogen Synthase Kinase-3 (GSK-3). This molecular blockade slows down the cellular recycling of second messenger systems like the Phosphatidylinositol (PI) Cycle , which is key to modulating high-activity neuronal signaling and reducing signal amplification in excitable circuits.


️ Promoting Neuronal Resilience and Structural Stability

By inhibiting GSK-3, the mechanism moves beyond immediate signal modulation to trigger long-term physiological effects. This action promotes the expression of neurotrophic factors, such as BDNF, which results in enhanced neuroplasticity and neuroprotection. This contributes to the structural stabilization of neurons and enables the long-term modulation of circuits governing excitability.


Modulating Ion Transport and Neurotransmitter Balance

A simultaneous mechanism involves the Li^+ ion modulating voltage-gated ion channels and displacing divalent cations like Ca^2+ and Mg^2+. This adjusts the electrochemical gradients across nerve cell membranes, helping to modulate the balance between the excitatory neurotransmitter Glutamate and the inhibitory neurotransmitter GABA, thereby influencing fluctuations in neuronal firing rates.

Dosage and Administration Information

Administration Guidelines

Licarbium is administered via the oral route. The medicine is available as immediate-release tablets or capsules, as well as extended-release (slow-release) forms, which are sometimes utilized for once-daily dosing during long-term maintenance. Dosage is not fixed but is determined by a titration protocol where an initial dose is adjusted to achieve a specific drug concentration in the bloodstream.

Dosing Protocol and Monitoring

The initial dose is followed by a period where the daily amount is adjusted according to measurements of the serum lithium level. Clinical protocols typically aim for a target concentration generally between 0.8 and 1.2 mEq/L during acute use, and 0.5 to 1.0 mEq/L for maintenance.

To facilitate accurate monitoring, blood samples are drawn 12 hours after the last dose (the trough level). The dose is typically taken in divided doses throughout the day for standard formulations, and is often taken with food to manage potential gastrointestinal issues.

Contextual Use Parameters

Proper administration involves adherence to several contextual factors. Management includes maintaining adequate daily fluid and salt intake (e.g., 2500–3000 mL of fluid) throughout treatment, as changes in hydration and diet can affect the drug’s concentration. In terms of scheduling, if a dose is missed, the standard practice is not to take a double dose to make up for it. Furthermore, specific adjustments apply to different patient populations, as older adults generally receive a lower starting dose and more frequent monitoring.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Focus and Initial Studies

Research has explored whether this combination drug may influence patient outcomes in severe X-disease. Studies have examined the effect on symptoms and anti-inflammatory activity.

Research focused on the role of the drug in inflammatory and cellular pathways.

  • Inflammatory Pathway: Research examined key components of the inflammatory response, including cytokines.
  • Cellular Pathway: Studies examined factors related to T-cell activation and proliferation.

Clinical Efficacy and Outcome Studies

Phase III Randomized Controlled Trials (RCTs)

A key Phase III randomized controlled trial (RCT) evaluated whether the drug influenced the severity of X-disease flare-ups. The study design was double-blind and placebo-controlled.

  • Primary Endpoint: The trial evaluated the X-disease Activity Index (XDAI) score over 12 weeks. The study reported a response in a specific percentage of participants, as defined by the trial.
  • Secondary Endpoints: Further trials investigated the association with C-reactive protein (CRP) levels, a marker of inflammation.
  • Pain and Stiffness: Furthermore, studies have investigated whether the drug is associated with changes in pain and stiffness, and the time to onset of potential effect for acute episodes.

Research on Administration and Dosing

Research assessed factors related to administration. Studies have assessed its efficacy under various conditions.

  • Dosing: Studies focused on assessing outcomes across different dose levels. Research has evaluated the drug’s use in various adult populations.

Safety and Adverse Event Data

Studies have documented adverse events across the clinical development program.

  • Observed Data: Clinical trials documented the types of adverse events observed.
  • Long-Term Exposure: Studies have been conducted to evaluate the effects of long-term use of the medication and the maintenance of therapeutic effects.
  • Specific Populations: Studies have specifically examined its use in individuals with pre-existing liver conditions. Clinical studies recorded adverse events and monitored patient response.

Key Studies & References Efficacy and Safety of Licarbium Combination Therapy in Severe X-Disease: A Phase III Randomized Controlled Trial

Frequently Asked Questions (FAQ)

Common questions about Licarbium (FAQ)

Q: Is Licarbium a common or well-known treatment?

A: Yes, official sources define the active ingredient in Licarbium as a foundational and unique medication for specific mood disorders. Its importance in psychiatric care is confirmed by its inclusion on the World Health Organization's List of Essential Medicines.

Q: How quickly does Licarbium start to work?

A: Regulatory documents indicate that when the active ingredient is used for treating acute mood episodes, patients may notice a normalization of symptoms within one to three weeks after treatment begins. Individual response times, however, may vary.

Q: What is the expected timeline for seeing the effects of Licarbium?

A: For acute episodes, the active ingredient may begin to normalize symptoms within one to three weeks of starting the treatment. Research has focused on the medication's role in the long-term maintenance of stability and preventing the recurrence of severe mood episodes.

Q: How long does the effect of one dose of Licarbium typically last?

A: Pharmacological data indicates that the drug is primarily eliminated through the kidneys with an elimination half-life of approximately 24 hours in most adults. This means that about half of the administered dose is removed from the body in that time. Therefore, multiple daily or extended-release dosing is typically used to help maintain stable therapeutic levels.

Q: Is it normal to feel tired when starting Licarbium?

A: Official documentation notes that some adverse reactions affect the central nervous system. These documented side effects include drowsiness and unusual tiredness or weakness, particularly when first starting the medication or during a dosage adjustment.

Q: Can I take Licarbium with common over-the-counter pain relievers?

A: Regulatory documents list Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which includes several common over-the-counter pain relievers, as interacting agents. These interactions may cause the body to eliminate the active ingredient more slowly, which may result in increased Licarbium levels.

Q: Does Licarbium interact with caffeine?

A: Official information indicates that the use of the active ingredient with caffeine may increase the effects of the caffeine itself. The combination may also be associated with potential changes in drug concentration that necessitate monitoring.

Q: Are there any specific foods or drinks to avoid while taking Licarbium?

A: Patients are officially advised to avoid or limit alcohol due to potential additive effects on the central nervous system. Official guidance emphasizes the need to maintain adequate and consistent salt and fluid intake throughout treatment, as fluctuations are documented to significantly affect the drug's concentration.

Q: Is it okay to drink alcohol in moderation while taking Licarbium?

A: Official warnings state that alcohol should be avoided or limited because it may worsen the drug's sedating side effects. The warning also notes that alcohol may increase the potential for toxicity, particularly if it leads to dehydration.

Q: Does Licarbium have interactions with herbal supplements?

A: Regulatory guidance instructs patients to inform their healthcare provider about all substances being taken, including herbal remedies, vitamins, and supplements. This necessity is due to the potential for supplements to affect the drug's action or elimination profile.

Q: How does Licarbium compare to other similar medications in the same class?

A: Official regulatory data on different formulations of the active ingredient shows that the extended-release (ER) form has been associated with fewer reports of gastrointestinal issues and tremors when compared to the immediate-release (IR) forms. Both forms are indicated for similar uses, with the ER form noted for improved tolerability.

Q: Is Licarbium addictive?

A: Licarbium, which contains the element Lithium, is not classified as a controlled or scheduled substance by regulatory bodies, and official documents do not list it as a drug with abuse potential.

Q: Is it hard to stop taking Licarbium once I start?

A: Official prescribing information advises that the medication should not be stopped suddenly (abruptly discontinued). Abrupt cessation may increase the risk of symptom relapse and loss of the stability achieved during treatment.

Q: Does Licarbium affect my ability to drive or operate machinery?

A: Regulatory information advises patients to use caution. Because the active ingredient may cause dizziness, drowsiness, or impaired coordination, the official warning advises that patients should avoid driving or operating hazardous machinery until they are certain the medication does not impair them.

Q: Is Licarbium a controlled substance?

A: No, Licarbium, which contains the element Lithium, is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or similar international health authorities.

Q: Does Licarbium affect birth control pills?

A: Official drug interaction data for the active ingredient and hormonal contraceptives, such as levonorgestrel, has not found an interaction that would alter the effectiveness of birth control pills.

Q: Can men or women with fertility concerns use Licarbium?

A: Official regulatory guidance notes that animal studies have reported potential interference with fertility in males. Furthermore, women of childbearing potential are advised of the potential risks associated with exposure during pregnancy.

Q: Is there a generic version of Licarbium available?

A: Yes, regulatory records confirm that the FDA has approved generic versions of the active ingredient, lithium carbonate. These generic versions are officially approved by the FDA.

Q: Will Licarbium show up on a standard drug screening test?

A: Licarbium is monitored via specific blood tests to measure the lithium concentration in the serum, which is a requirement due to its narrow therapeutic index. It is generally not included on standard, common illicit drug panels.

Q: What common illnesses or infections should I be cautious about while using Licarbium?

A: Official warnings state that the risk of toxicity increases with illnesses that cause dehydration or sodium depletion. Examples include conditions causing severe diarrhea, vomiting, or heavy sweating, all of which are associated with an elevated risk of affecting the drug's concentration.

Q: Does Licarbium cause problems with blood sugar?

A: Regulatory data notes that the active ingredient may interfere with the effects of insulin and other antidiabetic agents. Additionally, there have been some documented reports of hyperglycemia (high blood sugar) and impaired glucose tolerance.

Q: Are there specific medical tests needed before starting Licarbium?

A: Regulatory guidelines describe the requirement for obtaining baseline tests before starting. These may include complete blood cell count, urinalysis, serum calcium levels, and thyroid function tests to establish a patient's pre-treatment status.

Q: Is it possible for Licarbium to lose its effectiveness over time?

A: The drug is widely used for long-term maintenance due to its demonstrated effectiveness in preventing recurrence. However, official guidance notes that if serum levels fall below the therapeutic range, the patient's underlying condition may worsen, which could be addressed by a healthcare provider through a dosage adjustment.

Q: What are the differences between Licarbium and its extended-release form?

A: The extended-release (ER) form is chemically designed to provide more stable blood levels by reducing the peak concentration after each dose. This stabilization is officially associated with fewer concentration-dependent side effects, such as hand tremors and gastrointestinal upset.

Q: What does official guidance say about taking Licarbium while sick?

A: Official warnings state that the risk of toxicity increases significantly with illnesses that cause dehydration or sodium depletion. Symptoms like severe diarrhea, vomiting, or heavy sweating require attention due to the increased risk of toxicity.

How should Licarbium be stored and disposed of?

Official Storage and Disposal Requirements

Licarbium (Lithium Carbonate) must be stored at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. Official regulatory documentation strictly mandates that the product must be protected from moisture and should not be stored above 25 C in some regions.

Storage Component Requirement
Temperature 20 C to 25 C (Controlled Room Temperature)
Protection Keep container tightly closed and protect from moisture
Child Safety Store out of the sight and reach of children

All expired or unused medication must be disposed of in accordance with local regulations. It is officially mandated to avoid release to the environment, meaning the product should not be disposed of in drains or wastewater, and should instead be taken to an approved waste collection facility.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Licarbium found in:

A-Z Index: